- Home
- AMC vs NVAX Comparison
AMC vs NVAX Comparison
Compare AMC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- NVAX
- Stock Information
- Founded
- AMC 1920
- NVAX 1987
- Country
- AMC United States
- NVAX United States
- Employees
- AMC N/A
- NVAX N/A
- Industry
- AMC Movies/Entertainment
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMC Consumer Discretionary
- NVAX Health Care
- Exchange
- AMC Nasdaq
- NVAX Nasdaq
- Market Cap
- AMC 1.2B
- NVAX 1.3B
- IPO Year
- AMC 2013
- NVAX 1995
- Fundamental
- Price
- AMC $2.78
- NVAX $6.00
- Analyst Decision
- AMC Hold
- NVAX Buy
- Analyst Count
- AMC 7
- NVAX 6
- Target Price
- AMC $3.96
- NVAX $17.83
- AVG Volume (30 Days)
- AMC 8.9M
- NVAX 6.0M
- Earning Date
- AMC 05-07-2025
- NVAX 05-09-2025
- Dividend Yield
- AMC N/A
- NVAX N/A
- EPS Growth
- AMC N/A
- NVAX N/A
- EPS
- AMC N/A
- NVAX N/A
- Revenue
- AMC $4,637,200,000.00
- NVAX $682,162,000.00
- Revenue This Year
- AMC $9.46
- NVAX $1.07
- Revenue Next Year
- AMC $7.01
- NVAX N/A
- P/E Ratio
- AMC N/A
- NVAX N/A
- Revenue Growth
- AMC N/A
- NVAX N/A
- 52 Week Low
- AMC $2.45
- NVAX $3.81
- 52 Week High
- AMC $11.88
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- AMC 42.83
- NVAX 41.41
- Support Level
- AMC $2.85
- NVAX $5.01
- Resistance Level
- AMC $3.00
- NVAX $6.58
- Average True Range (ATR)
- AMC 0.17
- NVAX 0.65
- MACD
- AMC 0.02
- NVAX 0.02
- Stochastic Oscillator
- AMC 60.00
- NVAX 50.25
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.